Home/Orion Corporation/Outi Vaarala
OV

Outi Vaarala

Senior Vice President, Research and Development

Orion Corporation

Orion Corporation Pipeline

DrugIndicationPhase
ODM-208Metastatic Castration-Resistant Prostate Cancer (mCRPC)Phase 2
ODM-209Undisclosed OncologyPhase 1
ODM-212Malignant Pleural Mesothelioma (MPM) & Epithelioid Hemangioendothelioma (EHE)Phase 2
Darolutamide (Nubeqa®)Prostate Cancer (Various stages)Marketed / Phase 3
LevomedetomidinePost-operative Sedation / AgitationPhase 3